Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526041 | 1.00 | MAPT (0.65) | MAPTMEN1HTTKMT2ADGAT1 | |
| SCHEMBL2157955 | 0.93 | MAPT (0.65) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL1268279 | 0.86 | MAPT (0.85) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL12482070 | 0.84 | MAPT (0.57) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL14642415 | 0.84 | MAPT (0.65) | MAPTMEN1HTTKMT2ADGAT1 | |
| SCHEMBL13679575 | 0.84 | MAPT (0.73) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL13679552 | 0.83 | MAPT (0.69) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL12481506 | 0.83 | MAPT (0.55) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL14615282 | 0.82 | MAPT (0.68) | MAPTMEN1HTTKMT2ADGAT1 | |
| SCHEMBL13679580 | 0.81 | MAPT (0.67) | MAPTMEN1HTTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346499-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2011-07-27 | — | — | EP | claimed |
| WO-2010037715-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2010-04-08 | — | — | WO | claimed |
| EP-2661425-B1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3023097-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2617414-A2 | Smoothened antagonism for the treatment of hedgehog pathway-related disorders | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | MAPT 3245/4885MEN1 3364/4885HTT 1409/4885 |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | MAPT 3245/4885MEN1 3364/4885HTT 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.